Search for content, post, videos

KeyPlants ships vaccine manufacturing facility to Senegal

Project MADIBA facility

KeyPlants has shipped a first-of-its-kind vaccine manufacturing filling facility to Senegal in West Africa.

After the facility is installed and becomes fully operational later in 2022, it will be the only regional manufacturing hub on the continent outside of South Africa capable of producing finished COVID-19 and other life-saving vaccines, states KeyPlants.

“We are proud to leverage our extensive experience and expertise in modular facilities and off-site manufacturing to drive forward this important project. By doing so, we will help provide crucial access to lifesaving therapeutics for the African population,” says Jörgen Harrysson, CEO of KeyPlants.

 

Project MADIBA is led by Institut Pasteur de Dakar (IPD), a non-profit foundation concerned with promoting public health and well-being in Senegal and throughout Africa.

 

Realizing the vision of Projekt MADIBA

The shipment of this facility is an important step towards realizing the vision of Project MADIBA, led by Institut Pasteur de Dakar (IPD), a non-profit foundation concerned with promoting public health and well-being in Senegal and throughout Africa. The project enjoys strong support from the government of Senegal, Africa CDC, WHO, CEPI and other partners and is supported by a global collaboration of funders and companies. These include KeyPlants and MEDInstill, which provides the novel vaccine manufacturing equipment utilized in the facility.

 

Project MADIBA has the flexibility to facilitate the manufacture of additional therapeutics beyond mRNA vaccines and meet changing global health needs.

 

With the capacity to produce up to 300 million COVID-19 vaccine doses annually, Project MADIBA will revolutionize access to vaccines in Africa and implement a safe, financially sustainable, and autonomous infrastructure to secure vaccine access and equity for Africa, states KeyPlants. Due to the facility’s multi-suite drug substance and fill-finish capabilities, Project MADIBA has the flexibility to facilitate the manufacture of additional therapeutics beyond mRNA vaccines and meet changing global health needs. Additionally, the portable and prefabricated design of the facility means that it is well equipped to scale-up or scale-out in line with the evolving needs of the local community, the companies state.

A critical step

The African Union and Africa CDC has identified vaccine manufacturing as a priority to address vaccine inequity to the continent, setting a target to manufacture 60% of African vaccine supply by 2040 and vaccine autonomy by 2060. Project MADIBA is a critical first step in achieving this goal, with this facility to serve as a blueprint for future vaccine manufacturing facilities to be built across Africa.

“Over a year after lifesaving COVID-19 vaccines were made broadly available to high-income countries, only 15 percent of Africa has been fully immunized.”

“Over a year after lifesaving COVID-19 vaccines were made broadly available to high-income countries, only 15 percent of Africa has been fully immunized. Against this backdrop, IPD remains focused on our vision to build and operate a vaccine manufacturing facility in Senegal that can produce vaccines for Africa as soon as possible,” says Dr. Amadou Sall, Director of Institut Pasteur de Dakar.